
SNY
46.55 USD
+3.33%
Today
+4.50%
1D
Market is closed
Sun
Closed
Mon
3:00 AM ~ 12:00 PM
Tue
12:00 AM ~ 12:00 PM
Wed
12:00 AM ~ 12:00 PM
Thu
12:00 AM ~ 12:00 PM
Fri
12:00 AM ~ 11:00 PM
Sat
Closed
Information
Name
Sanofi Leveraged
Currency
USD
Core Leverage
1:2
Plus Leverage
1:2
Max Leverage
1:10
Overnight Fees Buy (Core Leverage)
-0.0190%
Overnight Fees Sell (Core Leverage)
0.0024%
Overnight Fees Buy (Plus Leverage)
-0.0190%
Overnight Fees Sell (Plus Leverage)
0.0024%
Overnight Fees Buy (Max Leverage)
-0.0190%
Overnight Fees Sell (Max Leverage)
0.0024%
Market Cap
113.15B
Avg Daily Volume
3.33M
52 Week High
50.61 USD
52 Week Low
39.07 USD
Trading Hours
See hours
Overnight Fees Calculator
| Daily Overnight Fee % | Daily Overnight Fee $ | |
|---|---|---|
| BUYS | -0.01900% | $(0.190) |
| SELLS | 0.00240% | $0.024 |
*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.
Business Summary
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Top News
Insmed
-1.57%
Sanofi
+4.50%
Insmed may be worth $170 to $210 a share in takeover, analyst
tradingview.com
1d ago

Insmed
-1.57%
Sanofi
+4.50%
Insmed jumps on report of Sanofi takeover interest
tradingview.com
1d ago

Sanofi
+4.50%
Jacobs_Engineering
-2.15%
Jacobs tapped by Sanofi for Frankfurt insulin facility
tradingview.com
2d ago

Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.

